Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus gemcitabine in platinum-ineligible advanced urothelial carcinoma
ChiCTR2100043077Phase 4Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Sep 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and gemcitabine in transitional cell carcinoma (TCC), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Objective response rate (ORR). Started Sep 2020; status: recruiting.
02
Drugs
camrelizumabgemcitabine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2100043077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043077.